Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 19/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509535 | 0.91 | PYGL (0.83) | PYGLHDAC1HDAC8HDAC6 | |
| SCHEMBL2900306 | 0.91 | PYGL (0.83) | PYGLHDAC1HDAC8HDAC6 | |
| SCHEMBL4699966 | 0.84 | PYGL (0.72) | PYGLHDAC1HDAC8HDAC6 | |
| SCHEMBL4699957 | 0.83 | PYGL (0.71) | PYGLHDAC1HDAC8HDAC6 | |
| SCHEMBL20601617 | 0.79 | PYGL (0.83) | PYGLHDAC1HDAC8HDAC6 | |
| SCHEMBL16147794 | 0.78 | KCNMA1 (0.67) | PYGL | |
| SCHEMBL20601662 | 0.77 | PYGL (0.82) | PYGLHDAC1HDAC8HDAC6 | |
| SCHEMBL2917610 | 0.75 | PYGL (0.76) | PYGL | |
| SCHEMBL22871266 | 0.75 | PYGL (0.64) | PYGL | |
| SCHEMBL6516959 | 0.75 | PYGL (0.66) | PYGLHDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497262-B1 | ACYL-4-CARBOXYPHENYLUREA DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-08-04 | — | — | EP | claimed |
| EP-1497262-B1 | ACYL-4-CARBOXYPHENYLUREA DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-08-04 | — | — | EP | disclosed |
| EP-1404650-B1 | CARBOXAMIDE-SUBSTITUTED PHENYLUREA DERIVATIVES AND METHOD FOR PRODUCTION THEREOF AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-02-13 | — | — | EP | disclosed |
| US-20050143456-A1 | Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-30 | — | — | US | disclosed |
| US-6812250-B2 | FOR THERAPY TYPE II DIABETES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-02 | — | — | US | disclosed |
| EP-1404650-A1 | CARBOXAMIDE-SUBSTITUTED PHENYLUREA DERIVATIVES AND METHOD FOR PRODUCTION THEREOF AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030176497-A1 | Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-09-18 | — | — | US | disclosed |
| WO-2002096864-A1 | CARBOXAMIDE-SUBSTITUTED PHENYLUREA DERIVATIVES AND METHOD FOR PRODUCTION THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143456-A1 | Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments | GLS, MPC2, PC | PYGL 102/4885HDAC1 3052/4885HDAC8 3216/4885 |
| US-20030176497-A1 | Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments | GLS, PC, CPS1 | PYGL 123/4885HDAC1 2691/4885HDAC8 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.